Pixantrone

DRUG4 trials

Sponsors

Robert Bosch Gesellschaft fuer medizinische Forschung mbH, CTI BioPharma, The Lymphoma Academic Research Organisation

Conditions

Aggressive Non-Hodgkin LymphomaAnthracycline-based antineoplastic therapy (standard of care/routine treatment)LymphomaMetastatic CancerSolid Tumor (Excluding CNS)

Phase 1

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment

WithdrawnNCT01632436

CTI BioPharmaMetastatic Cancer

Start: 2012-05-31End: 2018-02-28Updated: 2023-10-02

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

WithdrawnNCT02800889

CTI BioPharmaLymphoma, Solid Tumor (Excluding CNS)

Start: 2016-10-24End: 2018-07-10Updated: 2020-01-29

Phase 2

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

CompletedNCT03458260

The Lymphoma Academic Research OrganisationAggressive Non-Hodgkin Lymphoma

Start: 2018-12-26End: 2024-12-24Updated: 2026-03-10

Phase 4

Serial cardiac magnetic resonance imaging (CMR) with contrast agents and biomarker analysis for the detection of cardiotoxicity under anthracycline-containing cancer therapy - A monocentric, low interventional Phase IV pilot study

Not yet recruitingCTIS2025-521573-14-00

Robert Bosch Gesellschaft fuer medizinische Forschung mbHAnthracycline-based antineoplastic therapy (standard of care/routine treatment)

Target: 93Updated: 2025-12-11